MYSTERIOUS: 3 | Mind Blowing Facts

Five big global health wins in 2025 that will save millions of lives

From HIV to TB, scientists and doctors made breakthroughs in treatment and prevention of some of the world’s deadliest diseases

The Guardian - UK · Dec 22, 2025

3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains

GILD, AMAT, and QCOM all stand out for their capacity to generate cash flow, which allows them to increase value to shareholders through dividends and buybacks.

MarketBeat · Dec 15, 2025

HIV ‘vaccine’ will reach just 7% of people needed to end Aids pandemic

The figure comes as the UN reports a ‘devastating’ collapse of HIV prevention services around the world

The Independent UK · Dec 2, 2025

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.

Barchart · Oct 31, 2025

South Africa's health minister hails new HIV prevention jab but warns of limited supply

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool against the disease

The Independent UK · Oct 14, 2025

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

Benzinga · Oct 13, 2025

Landmark deals for cheaper ‘pandemic-ending’ HIV jab hailed as ‘huge’ step forward

Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – but aid cuts still risk its rollout

The Independent UK · Sep 25, 2025

Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic

Lenacapavir described as ‘next best thing’ to an HIV vaccine will cost $40 a year for each patient in 120 countries from 2027, funders say

The Guardian - UK · Sep 24, 2025

Cheaper HIV prevention jab to roll out in lower income countries in 2027

The twice-yearly drug has been hailed as a medical breakthrough that could change the course of the HIV epidemic.

Euronews · Sep 24, 2025

Biotech Sector May Flip to Market Leader by Year-End

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

MarketBeat · Sep 15, 2025